文献速递甲状腺与颈部外科围术期管理与 ERAS

甲状旁腺切除术与西那卡塞治疗三发性甲状旁腺功能亢进的比较:手术改善肾移植移植物存活

Parathyroidectomy versus Cinacalcet in the Management of Tertiary Hyperparathyroidism: Surgery Improves Renal Transplant Allograft Survival.
PubMed 文献 · Surgery · 2018-11-08

该回顾性单中心研究纳入2000至2017年133例三发性甲状旁腺功能亢进患者(33例接受甲状旁腺切除术、100例接受西那卡塞治疗),比较临床参数与结局。甲状旁腺切除术组甲状旁腺激素正常化更常见(67% vs 15%,P < .001)、肾移植移植物失败率更低(9% vs 33%,P = .007);多变量分析显示甲状旁腺切除术与移植物失败呈负相关(OR 0.20,95%CI 0.06-0.71,P = .013)。作者认为移植后1年西那卡塞控制甲状旁腺激素不佳者应考虑甲状旁腺切除术。

要点

  • 甲状旁腺切除术组移植物失败率9%,低于西那卡塞组的33%(P = .007)。
  • 多变量分析中甲状旁腺切除术与移植物失败负相关(OR 0.20,95%CI 0.06-0.71,P = .013)。
  • 移植后1年甲状旁腺激素控制不佳的西那卡塞患者可考虑甲状旁腺切除术。

核心结论

  • 三发性甲状旁腺功能亢进患者接受甲状旁腺切除术较西那卡塞治疗与更低的肾移植移植物失败率相关。
  • 移植后1年西那卡塞未能充分控制甲状旁腺激素者应考虑甲状旁腺切除术以预防潜在移植物失败。

研究设计与样本

  • 回顾性、单中心研究,纳入2000至2017年三发性甲状旁腺功能亢进患者。
  • 共133例患者,其中33例接受甲状旁腺切除术、100例接受西那卡塞治疗。
  • 比较两组临床参数与结局,包括肾移植移植物失败。
  • 中位肾移植移植物存活5.9年(四分位距4.0-9.0)。

主要发现

  • 两组在年龄、性别、体重指数、合并症、移植前透析时长、尸体供者使用及移植物功能延迟恢复率方面无差异。
  • 甲状旁腺切除术组甲状旁腺激素正常化更常见(67% vs 15%,P < .001)。
  • 甲状旁腺切除术组肾移植移植物失败率更低(9% vs 33%,P = .007)。
  • 两组中位移植后随访相似(7.0年,四分位距4.5-10.0)。
  • 西那卡塞组中移植后1年较高的中位甲状旁腺激素(pg/mL)与移植物失败相关(348 [四分位距204-493] vs 195 [四分位距147-297],P = .025)。

关键数值与推荐

  • 甲状旁腺激素正常化率:甲状旁腺切除术组67% vs 西那卡塞组15%(P < .001)。
  • 肾移植移植物失败率:甲状旁腺切除术组9% vs 西那卡塞组33%(P = .007)。
  • 多变量分析:甲状旁腺切除术与移植物失败负相关(OR 0.20,95%CI 0.06-0.71,P = .013),无其他相关因素。
  • 西那卡塞组移植后1年中位甲状旁腺激素(pg/mL):移植物失败者348(四分位距204-493) vs 195(四分位距147-297),P = .025。

临床怎么用

  • 对三发性甲状旁腺功能亢进且接受肾移植的患者,甲状旁腺切除术可作为改善移植物存活的治疗选择。
  • 移植后1年应评估西那卡塞治疗下的甲状旁腺激素控制情况,控制不佳者考虑转诊甲状旁腺切除术。

局限性

  • 回顾性、单中心设计,可能存在选择偏倚与混杂。
  • 甲状旁腺切除术组样本量较小(33例),西那卡塞组100例,组间样本量不均衡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Renal transplant allograft function in patients with tertiary hyperparathyroidism who are treated with cinacalcet versus parathyroidectomy remains unclear. METHODS: This is a retrospective, single-center review of patients with tertiary hyperparathyroidism between 2000 and 2017. We compared clinical parameters and outcomes, including renal allograft failure in patients who had undergone parathyroidectomy versus treatment with cinacalcet therapy. RESULTS: A total of 133 patients were included (33 who received parathyroidectomy and 100 who received cinacalcet); median renal allograft survival was 5.9 years (interquartile range 4.0-9.0). There were no differences in age, sex, body mass index, comorbidities, duration of pretransplant dialysis, cadaveric donor utilization, or rates of delayed allograft function between cohorts. In the parathyroidectomy cohort, normalization of parathyroid hormone occurred more frequently (67% vs 15%, P < .001) and renal allograft failure rates were less (9% vs 33%, P = .007), with similar median posttransplant follow-up (7.0 years [interquartile range 4.5-10.0]). On multivariable analysis, parathyroidectomy was inversely associated with allograft failure (odds ratio 0.20, 95%-confidence interval 0.06-0.71, P = .013); there were no other associated factors. A greater median parathyroid hormone (pg/mL) 1 year posttransplant (348 [interquartile range 204-493] vs 195 [interquartile range 147-297], P = .025) was associated with allograft failure in the cinacalcet cohort. CONCLUSION: Parathyroidectomy for tertiary hyperparathyroidism is associated with lesser rates of renal allograft failure compared with cinacalcet management. Patients with inadequate parathyroid hormone control on cinacalcet at 1 year posttransplant should be considered for parathyroidectomy to prevent potential allograft failure.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Finnerty BM, Chan TW, Jones G, et al. Parathyroidectomy versus Cinacalcet in the Management of Tertiary Hyperparathyroidism: Surgery Improves Renal Transplant Allograft Survival. Surgery. 2018. PMID: 30415867. doi:10.1016/j.surg.2018.04.090

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。